v3.20.1

Total revenues and other income - Recognition of payments (Details) € in Thousands, $ in Thousands |  |  | 12 Months Ended |
--- | --- | --- | --- | ---
Aug. 23, 2019 USD ($) | Aug. 23, 2019 EUR (€) | Jul. 14, 2019 USD ($) | Jul. 14, 2019 EUR (€) | Dec. 31, 2019 EUR (€) | Dec. 31, 2018 USD ($) | Dec. 31, 2018 EUR (€) | Dec. 31, 2017 USD ($) | Dec. 31, 2017 EUR (€) | Dec. 31, 2016 EUR (€)
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront received |  |  | $ 3,950,000 | € 3,569,800 |  |  |  |  |  |
Upfront Payment Received | $ 3,950,000 | € 3,569,800 |  |  |  |  |  |  |  |
Deferred income |  |  |  |  | € 3,000,646 |  | € 149,801 |  | € 219,892 | € 285,612
Revenue recognized |  |  |  |  | 844,985 |  | 288,836 |  | 127,087 |
Gilead |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront received |  |  |  |  | € 3,569,815 |  |  |  |  |
Gilead | Collaboration agreement for filgotinib, Milestone payments, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront received | $ |  |  |  |  |  | $ 15,000 |  |  |  |
Upfront Payment Received |  |  |  |  |  |  | 12,418 |  |  |
Gilead | Collaboration agreement for filgotinib, Upfront payment, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront received | $ |  |  |  |  |  |  |  | $ 300,000 |  |
Upfront Payment Received |  |  |  |  |  |  |  |  | 275,558 |
Gilead | Collaboration agreement for filgotinib, Subscription agreement, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Payment Received |  |  |  |  |  |  |  |  | 39,003 |
Deferred income |  |  |  |  |  |  |  |  | 39,000 |
Gilead | Collaboration agreement for filgotinib, Milestone payments, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront received | $ |  |  |  |  |  |  |  | 70,000 |  |
Upfront Payment Received |  |  |  |  |  |  |  |  | 64,435 |
Servier | Collaboration agreement for osteoarthritis, Milestone payment, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Payment Received |  |  |  |  |  |  | 9,000 |  |  |
Servier | Collaboration agreement for osteoarthritis, License fee, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Payment Received |  |  |  |  |  |  |  |  | 6,000 |
AbbVie | Collaboration agreement for CF, Upfront payment, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront received | $ |  |  |  |  |  | 45,000 |  |  |  |
Upfront Payment Received |  |  |  |  |  |  | 38,874 |  |  |
AbbVie | Collaboration agreement for CF, Milestone payments, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront received | $ |  |  |  |  |  | $ 10,000 |  |  |  |
Upfront Payment Received |  |  |  |  |  |  | 8,548 |  |  |
AbbVie | Collaboration agreement for CF, Upfront payments, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront received | $ |  |  |  |  |  |  |  | 45,000 |  |
Upfront Payment Received |  |  |  |  |  |  |  |  | 34,001 |
AbbVie | Collaboration agreement for CF, Milestone payments, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront received | $ |  |  |  |  |  |  |  | $ 77,500 |  |
Upfront Payment Received |  |  |  |  |  |  |  |  | 68,310 |
Novartis | Collaboration Agreement for MOR106, Upfront Payment, Current Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Payment Received |  |  |  |  |  |  | 47,500 |  |  |
IAS18 |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 232,800 |  | 127,087 |
IAS18 | Upfront and Milestone Payments and License Fees [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 213,845 |  |  |
IAS18 | Upfront and Milestone Payments and License Fees Current Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 115,503 |  |  |
IAS18 | Upfront Payments and License Fees, Current Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 85,537 |  |  |
IAS18 | Milestone Payments for Current Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 29,966 |  |  |
IAS18 | Upfront and Milestone Payments and License Fees, Prior Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  |  |  | 219,343 |
Revenue recognized |  |  |  |  |  |  | 98,342 |  | 114,921 |
IAS18 | Upfront Payments and License Fees, Prior Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  |  |  | 219,343 |
Revenue recognized |  |  |  |  |  |  | 98,342 |  | 71,971 |
IAS18 | Milestone Payments for Prior Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 42,950 |
IAS18 | Gilead | Collaboration agreement for filgotinib, Milestone payments, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 12,418 |  |  |
IAS18 | Gilead | Collaboration agreement for filgotinib, Upfront payment, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  |  |  | 187,449 |
Revenue recognized |  |  |  |  |  |  | 84,806 |  | 62,488 |
IAS18 | Gilead | Collaboration agreement for filgotinib, Subscription agreement, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  |  |  | 26,532 |
Revenue recognized |  |  |  |  |  |  | 12,004 |  | 8,845 |
IAS18 | Gilead | Collaboration agreement for filgotinib, Milestone payments, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 9,354 |
IAS18 | Servier | Collaboration agreement for osteoarthritis, Milestone payment, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 9,000 |  |  |
IAS18 | Servier | Collaboration agreement for osteoarthritis, License fee, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  |  |  | 5,362 |
Revenue recognized |  |  |  |  |  |  | 1,532 |  | 638 |
IAS18 | AbbVie | Collaboration agreement for CF, Upfront payment, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 38,037 |  |  |
IAS18 | AbbVie | Collaboration agreement for CF, Milestone payments, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 8,548 |  |  |
IAS18 | AbbVie | Collaboration agreement for CF, Milestone payments, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 33,596 |
IAS18 | Novartis | Collaboration Agreement for MOR106, Upfront Payment, Current Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 47,500 |  |  |
IFRS 15 |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 288,836 |  |  |
IFRS 15 | Upfront and Milestone Payments and License Fees [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 149,021 |  |  |
Revenue recognized |  |  |  |  |  |  | 269,881 |  |  |
IFRS 15 | Upfront and Milestone Payments and License Fees Current Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 5,646 |  |  |
Revenue recognized |  |  |  |  |  |  | 110,694 |  |  |
IFRS 15 | Upfront Payments and License Fees, Current Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 837 |  |  |
Revenue recognized |  |  |  |  |  |  | 85,537 |  |  |
IFRS 15 | Milestone Payments for Current Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 4,809 |  |  |
Revenue recognized |  |  |  |  |  |  | 25,157 |  |  |
IFRS 15 | Upfront and Milestone Payments and License Fees, Prior Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 143,375 |  | 302,563 |
Deferred income reclassified from equity |  |  |  |  |  |  |  |  | 83,220 |
Revenue recognized |  |  |  |  |  |  | 159,187 |  |  |
IFRS 15 | Upfront Payments and License Fees, Prior Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 117,903 |  | 228,853 |
Deferred income reclassified from equity |  |  |  |  |  |  |  |  | 9,510 |
Revenue recognized |  |  |  |  |  |  | 110,950 |  |  |
IFRS 15 | Milestone Payments for Prior Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 25,472 |  | 73,710 |
Deferred income reclassified from equity |  |  |  |  |  |  |  |  | 73,710 |
Revenue recognized |  |  |  |  |  |  | 48,237 |  |  |
IFRS 15 | Gilead | Collaboration agreement for filgotinib, Milestone payments, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 4,625 |  |  |
Revenue recognized |  |  |  |  |  |  | 7,793 |  |  |
IFRS 15 | Gilead | Collaboration agreement for filgotinib, Upfront payment, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 102,643 |  | 187,449 |
Revenue recognized |  |  |  |  |  |  | 84,806 |  |  |
IFRS 15 | Gilead | Collaboration agreement for filgotinib, Subscription agreement, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 14,528 |  | 26,532 |
Revenue recognized |  |  |  |  |  |  | 12,004 |  |  |
IFRS 15 | Gilead | Collaboration agreement for filgotinib, Milestone payments, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 24,001 |  | 43,832 |
Deferred income reclassified from equity |  |  |  |  |  |  |  |  | 43,832 |
Revenue recognized |  |  |  |  |  |  | 19,831 |  |  |
IFRS 15 | Servier | Collaboration agreement for osteoarthritis, Milestone payment, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 9,000 |  |  |
IFRS 15 | Servier | Collaboration agreement for osteoarthritis, License fee, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income reclassified from equity |  |  |  |  |  |  |  |  | (5,362) |
IFRS 15 | AbbVie | Collaboration agreement for CF, Upfront payment, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 837 |  |  |
Revenue recognized |  |  |  |  |  |  | 38,037 |  |  |
IFRS 15 | AbbVie | Collaboration agreement for CF, Milestone payments, Current Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 184 |  |  |
Revenue recognized |  |  |  |  |  |  | 8,364 |  |  |
IFRS 15 | AbbVie | Collaboration agreement for CF, Upfront payments, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 732 |  | 14,872 |
Deferred income reclassified from equity |  |  |  |  |  |  |  |  | 14,872 |
Revenue recognized |  |  |  |  |  |  | 14,140 |  |  |
IFRS 15 | AbbVie | Collaboration agreement for CF, Milestone payments, Prior Period [member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred income |  |  |  |  |  |  | 1,471 |  | 29,878 |
Deferred income reclassified from equity |  |  |  |  |  |  |  |  | € 29,878 |
Revenue recognized |  |  |  |  |  |  | 28,406 |  |  |
IFRS 15 | Novartis | Collaboration Agreement for MOR106, Upfront Payment, Current Period [Member] |  |  |  |  |  |  |  |  |  |
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | € 47,500 |  |  |

X
- Definition Deferred income reclassified from equity + References No definition available. + Details
Name: | glpg_DeferredIncomeReclassifiedFromEquity
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | glpg_IfrsCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash inflow received as upfront payment. + References No definition available. + Details
Name: | glpg_UpfrontPaymentReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payments, license fees, and milestones received + References No definition available. + Details
Name: | glpg_UpfrontPaymentsLicenseFeesAndMilestonesReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of liability representing income that has been received but is not yet earned. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 78 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_78&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DeferredIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Expiry date 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants. Effective 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 28 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_28_a&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 23 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23_a&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 32 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_32&doctype=Standard -URIDate 2019-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 33 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_33_a&doctype=Standard -URIDate 2019-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 34 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_34&doctype=Standard -URIDate 2019-03-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 82 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_82_a&doctype=Standard -URIDate 2019-03-27 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 103 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_103&doctype=Standard -URIDate 2019-03-27 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 102 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_102&doctype=Standard -URIDate 2019-03-27 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2019-01-01 -Paragraph 33 -Subparagraph b -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2019-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2019-03-27 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B12 -Subparagraph b -Clause v -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B -URIDate 2019-03-27 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B10 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_Revenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForFilgotinibMilestonePaymentsCurrentPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForFilgotinibUpfrontPaymentPriorPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForFilgotinibSubscriptionAgreementPriorPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForFilgotinibMilestonePaymentsPriorPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_ServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForOsteoarthritisMilestonePaymentCurrentPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForOsteoarthritisLicenseFeePriorPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_AbbvieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForCfUpfrontPaymentCurrentPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForCfMilestonePaymentsCurrentPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForCfUpfrontPaymentsPriorPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForCfMilestonePaymentsPriorPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForMor106UpfrontPaymentsCurrentPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=glpg_Ias18StandardMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_UpfrontAndMilestonePaymentsAndLicenseFeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_UpfrontAndMilestonePaymentsAndLicenseFeesCurrentPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_UpfrontPaymentsAndLicenseFeesCurrentPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_MilestonePaymentsForCurrentPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_UpfrontAndMilestonePaymentsAndLicenseFeesPriorPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_UpfrontPaymentsAndLicenseFeesPriorPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_MilestonePaymentsForPriorPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=glpg_Ifrs15Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |